Campaigning & Advocacy

As a charity we are actively involved in campaigning on behalf of patients and their carers, which we feel is an important part of the work that we do. We are passionate about doing everything we can to improve the experience of patients throughout their cancer journey.

Our campaigns

We run campaigns throughout the year, and need you to get involved and help raise awareness.

What is campaigning and advocacy?

As a charity we are actively involved in campaigning on behalf of patients and their carers, which we feel is an important part of the work that we do. We are passionate about doing everything we can to improve the experience of patients throughout their cancer journey.

Patient Advocacy Groups

We are involved with a number of organisations and coalitions on your behalf which, through collaborative working, aim to ensure that the collective voice of blood cancer patients is heard.

Working with the pharmaceutical industry

We work with the pharmaceutical industry to ensure that they take the interests of patients into account when developing new drugs and treatments for blood cancer patients.

Health Technology Appraisals

This involves working with bodies such as the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) to ensure that the views of patients are taken into account when making decisions over access to drugs and treatments.

Leukaemia Matters magazine

Leukaemia Matters magazine: where you'll feel informed, empowered, and supported.

Read More

Take a Moment to Catch Up

View our latest news and blog articles

August 14th

Six months of support: Our impact in 2025 so far

In the first half of 2025, Leukaemia Care has supported thousands through counselling, financial aid, trusted information and helpline advice — ensuring no one faces leukaemia alone. Discover our impact so far and how you can access support or help us reach even more people....

June 9th

Dalata and Leukaemia Care extend transformative partnership to 2028

Dalata’s Difference Makers aim to raise over €1 million for health and wellbeing charities...

June 9th

Ruxolitinib approved for patients with acute GvHD in England and Scotland

Leukaemia Care welcomes NICE and the SMC’s approval of ruxolitinib for patients with acute graft versus host disease (aGvHD) in England and Scotland....